» Articles » PMID: 35252174

Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer

Overview
Specialty Cell Biology
Date 2022 Mar 7
PMID 35252174
Authors
Affiliations
Soon will be listed here.
Abstract

Histone acetylation is one of the most common epigenetic modifications, which plays an important role in tumorigenesis. However, the prognostic role of histone acetylation-regulators in ovarian cancer (OC) remains little known. We compared the expression levels of 40 histone acetylation-related genes between 379 OC samples and 88 normal ovarian tissues and identified 37 differently expressed genes (DEGs). We further explored the prognostic roles of these DEGs, and 8 genes were found to be correlated with overall survival ( < 0.1). In the training stage, an 8 gene-based signature was conducted by the least absolute shrinkage and selector operator (LASSO) Cox regression. Patients in the training cohort were divided into two risk subgroups according to the risk score calculated by the 8-gene signature, and a notable difference of OS was found between the two subgroups ( < 0.001). The 8-gene risk model was then verified to have a well predictive role on OS in the external validation cohort. Combined with the clinical characteristics, the risk score was proved to be an independent risk factor for OS. In conclusion, the histone acetylation-based gene signature has a well predictive effect on the prognosis of OC and can potentially be applied for clinical treatments.

Citing Articles

Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9.

Fan T, Xiao C, Deng Z, Li S, Tian H, Zheng Y Respir Res. 2025; 26(1):17.

PMID: 39815269 PMC: 11734478. DOI: 10.1186/s12931-024-03093-6.


A novel histone acetylation-associated gene signature with prognostic value in Ewing sarcoma.

Wu A, Liu F, Zhou L, Jiang R, Yu S, Zhou Z Discov Oncol. 2024; 15(1):848.

PMID: 39738986 PMC: 11685356. DOI: 10.1007/s12672-024-01689-4.


Regulation of ovarian cancer by protein post-translational modifications.

Zhu Q, Zhou H, Xie F Front Oncol. 2024; 14:1437953.

PMID: 39678497 PMC: 11638062. DOI: 10.3389/fonc.2024.1437953.


Explore the expression of mitochondria-related genes to construct prognostic risk model for ovarian cancer and validate it, so as to provide optimized treatment for ovarian cancer.

Yunyun Z, Guihu W, An J Front Immunol. 2024; 15:1458264.

PMID: 39478854 PMC: 11521951. DOI: 10.3389/fimmu.2024.1458264.


RPS6KA1 is a histone acetylation-related oncoprotein in acute myeloid leukemia which is targeted by afzelin.

Guo X, Huang G, Qiu D, He H, Niu X, Guo Z BMC Cancer. 2024; 24(1):1189.

PMID: 39333927 PMC: 11438311. DOI: 10.1186/s12885-024-12886-3.


References
1.
Andrikopoulou A, Liontos M, Koutsoukos K, Dimopoulos M, Zagouri F . Clinical perspectives of BET inhibition in ovarian cancer. Cell Oncol (Dordr). 2021; 44(2):237-249. DOI: 10.1007/s13402-020-00578-6. View

2.
Wang W, Im J, Kim S, Jang S, Han Y, Yang K . ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer. Antioxidants (Basel). 2020; 9(11). PMC: 7698236. DOI: 10.3390/antiox9111137. View

3.
Doo D, Meza-Perez S, Londono A, Goldsberry W, Katre A, Boone J . Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer. Ther Adv Med Oncol. 2020; 12:1758835920913798. PMC: 7158255. DOI: 10.1177/1758835920913798. View

4.
Teng C, Zheng H . Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer. Oncol Lett. 2017; 14(4):4277-4281. PMC: 5604148. DOI: 10.3892/ol.2017.6714. View

5.
Krzeslak A, Forma E, Bernaciak M, Romanowicz H, Brys M . Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med. 2011; 12(1):61-5. PMC: 3295997. DOI: 10.1007/s10238-011-0138-5. View